NCT01480154View on ClinicalTrials.gov

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 23, 2011

Primary Completion Date

February 14, 2020

Study Completion Date

March 19, 2026

Conditions
Advanced Malignant Solid NeoplasmStage III Cutaneous Melanoma AJCC v7Stage III Prostate Cancer AJCC v7Stage III Renal Cell Cancer AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Stage IV Prostate Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7
Interventions
DRUG

Akt Inhibitor MK2206

Given PO

DRUG

Hydroxychloroquine

Given PO

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH